See more : Tara Chand Infra Soln Ltd (TARACHAND.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Cyclo Therapeutics, Inc. (CYTH) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cyclo Therapeutics, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Crown Proptech Acquisitions (CPTK) Income Statement Analysis – Financial Results
- J&V Energy Technology Co., Ltd. (6869.TW) Income Statement Analysis – Financial Results
- Autoliv, Inc. (0HJH.L) Income Statement Analysis – Financial Results
- Solidion Technology Inc. (STI) Income Statement Analysis – Financial Results
- Ramsay Health Care Limited (RHC.AX) Income Statement Analysis – Financial Results
Cyclo Therapeutics, Inc. (CYTH)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.cyclotherapeutics.com
About Cyclo Therapeutics, Inc.
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of Alzheimer's disease. In addition, it sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is based in Gainesville, Florida.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.08M | 1.38M | 1.59M | 903.38K | 1.01M | 1.01M | 1.24M | 1.50M | 950.46K | 1.57M | 1.69M | 1.04M | 1.03M | 802.37K | 623.87K | 494.94K | 751.18K | 542.31K | 454.36K | 464.69K | 394.53K | 522.37K | 289.43K | 384.59K |
| Cost of Revenue | 98.46K | 138.93K | 156.08K | 66.40K | 75.49K | 105.03K | 132.92K | 198.43K | 124.43K | 272.64K | 426.02K | 139.68K | 273.76K | 114.66K | 110.83K | 99.32K | 118.40K | 125.19K | 66.66K | 78.83K | 45.43K | 84.48K | 34.03K | 99.22K |
| Gross Profit | 977.95K | 1.24M | 1.43M | 836.98K | 931.71K | 906.45K | 1.10M | 1.30M | 826.03K | 1.29M | 1.27M | 905.27K | 758.09K | 687.71K | 513.04K | 395.62K | 632.77K | 417.13K | 387.70K | 385.87K | 349.10K | 437.89K | 255.40K | 285.37K |
| Gross Profit Ratio | 90.85% | 89.90% | 90.16% | 92.65% | 92.50% | 89.62% | 89.26% | 86.80% | 86.91% | 82.61% | 74.84% | 86.63% | 73.47% | 85.71% | 82.24% | 79.93% | 84.24% | 76.92% | 85.33% | 83.04% | 88.48% | 83.83% | 88.24% | 74.20% |
| Research & Development | 14.18M | 9.00M | 9.15M | 6.10M | 4.87M | 2.71M | 2.29M | 1.86M | 658.51K | 94.13K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 5.66M | 7.81M | 6.50M | 3.68M | 3.43M | 2.43M | 2.62M | 2.64M | 2.22M | 1.53M | 639.54K | 560.17K | 799.60K | 678.64K | 693.33K | 520.06K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 3.90K | 13.06K | 18.34K | 5.01K | 5.89K | 5.64K | 7.85K | 7.16K | 7.57K | 10.90K | 8.91K | 10.81K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.83M | 7.82M | 6.52M | 3.68M | 3.44M | 2.44M | 2.63M | 2.65M | 2.23M | 1.55M | 648.45K | 570.98K | 799.60K | 678.64K | 693.33K | 520.06K | 439.10K | 350.68K | 500.32K | 664.78K | 263.50K | 240.54K | 279.11K | 548.79K |
| Other Expenses | 0.00 | 30.50K | 27.54K | 19.95K | 13.98K | 13.95K | 19.77K | 130.95K | 202.02K | 217.52K | 188.76K | 159.93K | 32.75K | 20.94K | 20.65K | 22.87K | 439.10K | 350.68K | 500.32K | 664.78K | 263.50K | 240.54K | 279.11K | 575.21K |
| Operating Expenses | 21.04M | 16.85M | 15.70M | 9.80M | 8.32M | 5.16M | 4.95M | 4.65M | 3.09M | 1.86M | 837.21K | 730.91K | 832.35K | 699.58K | 713.98K | 542.93K | 439.10K | 350.68K | 500.32K | 664.78K | 263.50K | 240.54K | 279.11K | 575.21K |
| Cost & Expenses | 21.13M | 16.99M | 15.85M | 9.86M | 8.40M | 5.27M | 5.08M | 4.85M | 3.22M | 2.13M | 1.26M | 870.59K | 1.11M | 814.24K | 824.81K | 642.25K | 557.51K | 475.86K | 566.97K | 743.61K | 308.93K | 325.02K | 313.14K | 674.43K |
| Interest Income | 0.00 | 12.47K | 3.41K | 19.80K | 12.03K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.51K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 28.60K | 31.29K | 33.67K | 53.87K | 61.80K | 25.81K | 4.31K | 0.00 | 1.82K | 10.75K | 11.05K | 13.96K | 12.03K | 22.60K | 30.92K | 35.44K | 28.29K | |
| Depreciation & Amortization | 19.28K | 19.48K | 16.83K | 12.76K | 5.68K | 10.12K | 9.27K | 107.10K | 169.03K | 152.45K | 148.04K | 142.64K | 32.75K | 20.94K | 20.58K | 22.87K | 24.37K | 27.46K | 35.01K | 27.76K | 37.82K | 24.19K | 51.29K | 26.41K |
| EBITDA | -20.03M | -15.60M | -14.27M | -8.95M | -7.39M | -4.24M | -3.82M | -4.09M | -2.23M | -406.57K | 486.82K | 303.65K | -39.21K | 12.72K | -172.55K | -188.55K | 218.04K | -63.32K | -77.60K | -251.15K | 90.92K | 221.54K | 27.58K | -66.02K |
| EBITDA Ratio | -1,860.90% | -1,145.03% | -897.54% | -992.49% | -719.16% | -419.60% | -309.54% | -215.26% | -220.57% | -26.15% | 34.14% | 30.34% | -4.02% | 1.13% | -28.91% | -25.14% | 26.28% | 46.31% | -56.50% | 4.17% | 29.51% | 42.57% | 8.63% | -69.09% |
| Operating Income | -20.05M | -15.61M | -14.27M | -8.96M | -7.39M | -4.27M | -3.84M | -4.21M | -2.41M | -562.31K | 336.65K | 157.49K | -74.26K | -11.87K | -200.94K | -239.47K | 193.67K | -45.90K | -112.61K | -278.91K | 85.60K | 197.35K | -23.71K | -289.84K |
| Operating Income Ratio | -1,862.69% | -1,134.76% | -899.77% | -991.85% | -733.80% | -421.84% | -310.51% | -279.85% | -253.22% | -35.87% | 19.88% | 15.07% | -7.20% | -1.48% | -32.21% | -48.38% | 25.78% | -8.46% | -24.78% | -60.02% | 21.70% | 37.78% | -8.19% | -75.36% |
| Total Other Income/Expenses | -7.25K | 171.00K | 3.41K | 19.80K | 12.03K | 11.77K | 10.26K | -17.95K | -24.62K | -30.37K | -51.74K | -58.29K | -23.51K | -662.00 | 7.81K | 26.24K | 9.89K | -168.28K | 165.15K | -282.58K | -15.63K | -31.77K | -32.83K | 171.41K |
| Income Before Tax | -20.06M | -15.45M | -14.29M | -8.94M | -7.53M | -4.26M | -3.83M | -4.22M | -2.43M | -592.69K | 284.91K | 99.20K | -97.77K | -12.53K | -193.13K | -213.23K | 203.55K | -101.83K | 52.54K | -561.49K | 69.98K | 165.58K | -56.54K | -315.83K |
| Income Before Tax Ratio | -1,863.36% | -1,123.08% | -900.94% | -989.80% | -747.87% | -420.68% | -309.68% | -281.04% | -255.81% | -37.81% | 16.83% | 9.49% | -9.47% | -1.56% | -30.96% | -43.08% | 27.10% | -18.78% | 11.56% | -120.83% | 17.74% | 31.70% | -19.54% | -82.12% |
| Income Tax Expense | 0.00 | -171.00K | 18.52K | -18.53K | 141.75K | 11.77K | 0.00 | 28.60K | 120.00K | 33.67K | 80.00K | 25.00K | 25.81K | 25.00K | 0.00 | 200.00K | -450.00K | 168.28K | 225.00K | 282.58K | -225.00K | 31.77K | 90.17K | 195.00K |
| Net Income | -20.06M | -15.28M | -14.31M | -8.92M | -7.67M | -4.26M | -3.83M | -4.22M | -2.55M | -592.69K | 204.91K | 74.20K | -97.77K | -37.53K | -193.13K | -413.23K | 653.55K | -101.83K | -172.46K | -561.49K | 294.98K | 165.58K | -113.88K | -510.83K |
| Net Income Ratio | -1,863.36% | -1,110.65% | -902.10% | -987.75% | -761.94% | -420.68% | -309.68% | -281.04% | -268.44% | -37.81% | 12.10% | 7.10% | -9.47% | -4.68% | -30.96% | -83.49% | 87.00% | -18.78% | -37.96% | -120.83% | 74.77% | 31.70% | -39.35% | -132.82% |
| EPS | -1.23 | -1.81 | -2.25 | -5.58 | -7.09 | -5.20 | -5.32 | -6.67 | -4.54 | -1.17 | 1.00 | 1.00 | -0.27 | -0.11 | -0.67 | -1.76 | 3.60 | -0.69 | -1.44 | -7.76 | 5.00 | 3.00 | -2.59 | -13.80 |
| EPS Diluted | -1.23 | -1.81 | -2.25 | -5.58 | -7.09 | -5.20 | -5.32 | -6.67 | -4.54 | -1.17 | 1.00 | 1.00 | -0.27 | -0.11 | -0.67 | -1.76 | 3.60 | -0.69 | -1.44 | -7.76 | 5.00 | 3.00 | -2.59 | -13.80 |
| Weighted Avg Shares Out | 16.33M | 8.44M | 6.37M | 1.60M | 1.08M | 817.57K | 720.37K | 633.54K | 562.09K | 505.43K | 371.66K | 366.80K | 358.07K | 337.11K | 287.51K | 235.33K | 179.20K | 148.15K | 120.18K | 72.32K | 50.05K | 47.91K | 43.89K | 37.02K |
| Weighted Avg Shares Out (Dil) | 16.33M | 8.44M | 6.37M | 1.60M | 1.08M | 817.57K | 720.37K | 633.54K | 562.09K | 505.43K | 371.66K | 366.80K | 358.07K | 337.11K | 287.51K | 235.33K | 179.20K | 148.15K | 120.18K | 72.32K | 50.05K | 47.91K | 43.89K | 37.02K |
Cyclo Therapeutics Announces Abstract Accepted for Poster Presentation at the 14th International Congress of Inborn Errors of Metabolism (ICIEM)
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced its abstract has been selected...
Cyclo Therapeutics to Participate in the 2021 Virtual Cyclodextrin Conference Hosted by CycloLab
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced it will participate in the...
Cyclo Therapeutics Appoints Lise Lund Kjems, MD, PhD as Chief Medical Officer
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced the appointment of Lise Lund...
Cyclo Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that N. Scott Fine, Chief...
Cyclo Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that N. Scott Fine, Chief...
Cyclo Therapeutics Provides Business Update and Reports Second Quarter 2021 Financial Results
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today reported its financial results for the...
Cyclo Therapeutics Announces New Positive Safety and Efficacy Data from Ongoing Phase 1 Open-Label Extension Study of Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced new data from its Phase...
Cyclo Therapeutics Commences Commercial-Scale Manufacturing for Trappsol® Cyclo™
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that it has commenced the...
Cyclo Therapeutics to Present at the 2021 NPC Patient and Family Conference Hosted by the Australian NPC Disease Foundation
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced it will present at the...
Cyclo Therapeutics Shares Move Higher On Kickstart Of Late-Stage NPC Trial With Trappsol Cyclo
Cyclo Therapeutics Inc (NASDAQ: CYTH) has commenced its pivotal Phase 3 study (TransportNPC) evaluating Trappsol Cyclo for Niemann-Pick Disease Type C1 (NPC1). The TransportNPC study has the regulatory and IRB approval required to commence patient enrollment, and site activation is underway.
Source: https://incomestatements.info
Category: Stock Reports